Lawsuit context and why it matters for Lufax Holding (NYSE:LU)

Rosen Law Firm has filed a class action lawsuit against Lufax Holding (NYSE:LU), alleging misleading statements, weak internal controls, and misstated financial results during the April 2023 to January 2025 period.

For current and prospective shareholders, this kind of legal action can influence perceptions of risk, capital access, and the level of confidence investors place in the company’s reported numbers and governance practices.

Lufax Holding’s share price has come under pressure, with a 30 day share price return of 23.46% and a year to date share price return of 30.86% decline. The 1 year total shareholder return is 35.86% lower, pointing to fading momentum as the class action adds another layer of perceived risk.

If this lawsuit has you rethinking where risk and opportunity might sit next, it could be a good moment to size up 20 top founder-led companies

With Lufax shares under pressure, trading around US$1.86 and sitting at a large discount to the average analyst price target, you have to ask whether this legal overhang is creating a potential entry point or if the market is already bracing for weaker growth.

Preferred Price-to-Sales of 0.4x: Is it justified?

Lufax Holding is currently trading on a P/S of 0.4x, which, at a last close of $1.86, sits well below both peers and the broader Consumer Finance industry.

The P/S multiple compares the company’s market value to its revenue and is often used for businesses that are unprofitable, as is the case with Lufax today. For readers weighing this against the lawsuit headlines, the P/S metric provides an earnings-independent view of what the market is willing to pay for each dollar of reported sales.

Here, the market is assigning Lufax a P/S of 0.4x compared to a peer average of 1x and a US Consumer Finance industry average of 1.2x. Against an estimated fair P/S of 1.7x, this represents a wider gap, indicating that the current multiple is well below the level suggested by certain quantitative models that compare the company with its peers.

Result: Price-to-Sales of 0.4x (UNDERVALUED)

However, this depends on legal outcomes and on Lufax reversing a net loss of CN¥3,870.62m, both of which could keep pressure on the shares.

Next Steps

With sentiment clearly mixed in this article, it can help to look past the headlines and weigh the numbers yourself while others react. To see what the current optimism is based on, review the 2 key rewards

Looking for more investment ideas?

If this lawsuit has sharpened your focus on risk and reward, you can use it as a springboard to compare other opportunities and stress test your portfolio choices.

• Spot potential value plays early by reviewing 62 high quality undervalued stocks that pair quality fundamentals with pricing that still looks compressed.
• Prioritise resilience by scanning 67 resilient stocks with low risk scores that score well on financial strength and lower volatility.
• Hunt for future standouts by checking the screener containing 25 high quality undiscovered gems that have strong fundamentals yet remain off most investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.